cyrilzakka/clinical-trials huggingface dataset:
Trained Immunity in Thyroid Carcinoma and Colon Carcinoma

Tumor-related inflammation is one of the hallmarks of cancers in general. Innate immunity specifically is a common denominator which is involved in the pathogenesis of both thyroid carcinoma and colon carcinoma. To improve the patient's outcome and identify novel therapeutic targets, one needs a deeper understanding of the tumor-induced changes in the bone marrow myeloid progenitor cells. Furthermore, treatment of these cells by nanoparticles or other agents that induce a program of 'trained immunity' may be a novel way to re-educate myeloid cells and their bone marrow progenitors in thyroid carcinoma patients. Lastly, the investigators expect that this approach could be effective also in other cancers of which colon carcinoma is here proposed as an additional model.

The investigators hypothesize that by exposing myeloid cells or their progenitors to various agents that induce trained immunity (e.g. high-density-lipoprotein-methylene diphosphonate nanoparticles, recombinant and synthetic cytokines), these immune cells will undergo functional reprogramming to induce a tumor-suppressive phenotype. In the future, this could be explored as a novel immunotherapy for tumors that are refractory to conventional treatment.


Eligibility Criteria:
Inclusion Criteria:

* At least 18 years old and mentally competent
* Newly diagnoses non-medullary thyroid carcinoma or colon carcinoma that is therapy naïve
* Planned to receive conventional treatment for the malignancy by surgery

Exclusion Criteria:

* Mentally incompetent
* Pregnant or breastfeeding
* Known inflammation or infectious disease or an immunosuppressive status
* Using medication interfering with the immune system
* Reduced platelets counts or other conditions associated with an increased risk of bleeding
* Severe comorbidities: other active malignancy (except for basal cell carcinoma and other in situ carcinomas)
* Previous anti-cancer treatment, such as chemotherapy, radiotherapy or surgical removal or the primary tumor
* Serious psychiatric pathology
* A self-reported alcohol consumption of \>21 units per week
The Stockholm Sleepy Brain Study: Effects of Sleep Deprivation on Cognitive and Emotional Processing in Young and Old

The main purpose of this study is to investigate the effects of partial sleep deprivation (PSD) on resting state brain connectivity, emotional contagion, empathy, and emotional regulation.


Eligibility Criteria:
Inclusion Criteria:

* 20-30 years of age, inclusive OR 65-75 years of age, inclusive
* Able to understand spoken and written Swedish (in order to understand instructions)
* Normal or corrected-to-normal vision not using glasses
* Not colour blind
* Right-handed
* Free from ferromagnetic objects in body
* No history of any neurologic or psychiatric illness including drug abuse
* No history of diabetes nor hypertension

  * No depression according to ratings using the Hospital Anxiety and Depression scale (HAD)
  * No insomnia according to ratings using the Insomnia Severity Index (ISI) and Karolinska Sleep Questionnaire (KSQ)
* No use of psychotropic drugs
* Not studying or working in medicine, psychology, nor behavioural science
* Not suffering from severe seasonal allergy
* No use of cortisone, anti-histamines, nor any other immune-modulating drugs
* Habitual intake of no more than 4 cups of coffee per day or the equivalent in terms of caffeine
* No daily use of nicotine

Exclusion Criteria:

-
National Comprehensive Cancer Network (NCCN) Decision Support Tool for Patients With NSCLC

This study involves the evaluation of a decision support tool, based on the patient version of the NCCN guidelines, for the non-small cell lung cancer patient population.

This study involves the evaluation of a decision support tool, based on the patient version of the NCCN guidelines, for the non-small cell lung cancer patient population. The decision support tool is offered by a trained coordinator to the patient and then utilized during an initial consultation. Patients complete forms before and after the visit indicating their level of decisional conflict, satisfaction, and satisfaction with decision. Pre-determined indices of quality of care were also collected by the study team.

Eligibility Criteria:
Inclusion Criteria:

* Over age of 18
* Able to provide informed consent
* Able to use a web-based interface
* Histologically proven or clinically apparent diagnosis of non-small cell lung cancer
* Newly diagnosed, with new primary occurrence of NSCLC, or diagnosed with a new recurrence or new progression of existing disease, and not yet treated for the new problem
* Being seen in consultation at thoracic oncology clinics

Exclusion Criteria:

* Unable to fill out questionnaires
* Already treated for the current diagnosis of a new primary occurrence of NSCLC, or already treated for the new recurrence or new progression of existing disease
BE WELL With Migraine: Brain Education and WELLness With Migraine

The goal of this randomized clinical trial is to evaluate two different non-drug, virtual treatment options designed to improve the lives of patients with migraine. Both interventions involve 8 weekly sessions and an online platform with additional content and learning. Participants can stay on all their medications during this study. Information from this study may help determine how to better treat migraine.

This study involves 8 weekly virtual sessions \& an online platform designed to improve the lives of patients with migraine. Participants from across the United States with migraine may be eligible to participate. This study does not require any in-person visits. All assessments and surveys will be completed virtually and/or online. Participants will independently complete an initial online screen. Participants will attend a scheduled phone or videoconferencing call with a study team member to complete the baseline assessment and learn how to use the online platform. Participants will keep an online daily headache log and complete several online surveys throughout the study.

Eligibility Criteria:
Inclusion Criteria:

* Diagnosis of migraine with or without aura by with headache frequency of 4-20 days/month
* At least 1 year of migraine
* At least 18 years old
* Able to participate in 8 weekly online classes
* Willingness to complete baseline headache logs
* Headache-related disability (Headache Impact Test (HIT)-6) score \>50
* Fluent in English
* Completion of technology onboarding with the online platform
* Pregnant women who are less than or equal to 16 weeks gestation at enrollment are allowed to participate

Exclusion Criteria:

* Major unstable medical/psychiatric condition that could be unsafe for participants or for the group environment.
* Medication overuse headache, with migraine treatment
* Pregnant women who are more than 16 weeks gestation at enrollment
* Unstable migraine treatment at enrollment: any preventive treatment (oral or injectable medication or neuromodulatory device) started within 12 weeks OR acute treatment within 4 weeks to ensure stability
* Unwillingness to maintain stable current medication dosages for study duration
* Failure to complete baseline headache logs
* Heavy alcohol and illicit drug use
* Participation in another intervention clinical trial or one that would interfere in this study
* Experience with stress reduction training (daily meditation practice, regular use of a mindfulness app, or prior experience with MBSR)
* Any, and all other diagnoses or conditions which, in the opinion of the site investigator, would prevent the patient from being a suitable candidate for the study or interfere with the medical care needs of the study participant: COVID-positive test within 30 days of enrollment
Airway Clearance Therapy on Hyperpolarized 129Xenon and MRI

This is an observational cohort study building on an existing protocol at our institution recruiting CF patients who are 6-21 years old with one or two copies of the F508del CFTR mutation. That existing protocol seeks to enroll a total of 38 subjects; it includes three to four (three scheduled, with a fourth optional) study visits, with spirometry, LCI, UTE MRI, and 129Xe MRI being performed at each visit. This present study will utilize existing study visits for the NHLBI study, with a sub-set of 20 subjects opting-in to have all of the procedures performed twice, with an intervening ACT, during one of their study visits.

This is an observational cohort study building on an existing protocol at our institution recruiting CF patients who are 6-21 years old with one or two copies of the F508del CFTR mutation. The existing protocol is funded by the NHLBI under R01-11863962 (PIs Woods, Clancy, and hereafter referred to as "the NHLBI study" for simplicity), and seeks to enroll a total of 38 subjects; it includes three to four (three scheduled, with a fourth optional) study visits, with spirometry, LCI, UTE MRI, and 129Xe MRI being performed at each visit. This present study will utilize existing study visits for the NHLBI study, with patients opting-in to have all of the procedures performed twice, with an intervening ACT, during one their study visits. The target enrollment is 20 subjects.

Airway clearance therapy (ACT) is used for treating cystic fibrosis (CF). It is known to impact measures of lung function, and while an increasing number of lung function measures are used in clinical trials, there has been no direct comparison of the effects of ACT across the different modalities. This study is actively investigating the relationship between different measures of lung function, comparing a spirometric measure (FEV1 percent-predicted) with measures of whole-lung ventilation (lung clearance index, or LCI) and regional assessments of both structure (with ultra-short echo time magnetic resonance imaging, or UTE MRI) and function (with hyperpolarized xenon, or 129Xe, MRI). Performing these assessments on CF patients will help to elucidate the relative sensitivity of each measure to intra-individual changes within the lung and will help guide the selection of lung function measures in future studies.

Eligibility Criteria:
Inclusion Criteria:

* Male or female between the ages of 6 through 21 years
* CFTR genotypes as specified in NHLBI study:

Two copies of the F508del CFTR mutation, OR Two non-functional CFTR mutations with one of them being F508del CFTR mutation

• Able to perform acceptable and repeatable spirometry

Exclusion Criteria:

* FEV1 percent predicted of \<60%
* standard MRI exclusions (metal implants, claustrophobia)
* pregnancy
Efficacy and Safety of IV Diclofenac (DIC075V) for Pain After Abdominal or Pelvic Surgery

This study will compare repeated intermittent IV dosing of diclofenac in patients with moderate to severe post-surgical pain from abdominal or pelvic surgery.

The primary objective is to evaluate the efficacy and safety of two dosage levels of parenteral diclofenac in providing pain relief as compared to placebo or Ketorolac tromethamine.

Eligibility Criteria:
Inclusion Criteria:

* Scheduled within two weeks of the screening visit to undergo abdominal or pelvic surgery
* Moderate to severe pain within 6 hours following completion of the required surgery.

Exclusion Criteria:

* Surgical procedure involves a subcostal incision.
* Chronic disease or recent cardiovascular events.
* Known allergy or hypersensitivity to the active compounds or any of the excipients used in the study.

Additional Inclusion/Exclusion Criteria May Apply
Buparid/PARI SINUS Versus Budes® Nasal Spray in the Therapy of Chronic Rhinosinusitis With Polyposis Nasi

The study should create data for the selection of a clinically relevant primary endpoint to assess the efficacy and safety of Buparid/PARI SINUS as compared to Budes Nasal Spray in the therapy of chronic rhinosinusitis (CRS) with polyposis nasi in adult patients. Ideally, the selected parameter should allow a correlation between an objective methodology and the clinical outcome of the study patients.


Eligibility Criteria:
Inclusion Criteria:

* Patient with confirmed diagnosis of chronic rhinosinusitis (CRS) with polyposis nasi grade I-III
* Patient with a PNIF of \> 7 l/min separated for left and right side of the nose
* Patient's written informed consent
* Male or female,\>= 18 years of age
* Patient is able to undergo nasal therapy without restrictions
* Capable of understanding the purpose and risk of the clinical trial
* Female patients with childbearing potential must have a negative urine pregnancy test prior to first IMP administration
* Patient has completed correctly the diary during the Wash-in Phase

Exclusion Criteria:

* Patients with cystic fibrosis
* Patients with polyposis nasi grade IV
* Patients with prior sinonasal surgery (exemption: polypectomy)
* Patients with primary ciliaritis
* Pregnant or breastfeeding women
* Patients with suspected active upper airway infection
* Receipt of an investigational drug as part of a clinical trial within 4 weeks prior to first administration of IMP
* Drug or alcohol abuse
* End-stage malignancies
* Known hypersensitivity to Budesonide
* Patients with oral steroid therapy within the last 4 weeks
* Patients with frequent epistaxis (\> 2 per month)
Role of Pentoxifylline and Celecoxib in Parkinsonism

Parkinson's disease (PD) is a chronic neurodegenerative disease clinically characterized by bradykinesia, hypokinesia, rigidity, resting tremor, and postural instability. These motor manifestations are attributed to the degeneration and selective loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc), leading to a dopamine (DA) deficiency in the striatum.

The environmental factors are the most common risk factor for Parkinson's disease, while hereditary determinants have minor role for disease. Furthermore, the clinical diagnosis of PD rests on the identification of characteristics related to dopamine deficiency. However, nondopaminergic and nonmotor symptoms, including cognitive dysfunction and depression, which is one of the most common and persistent symptoms, are sometimes present at an earlier disease stage and, almost inevitably, emerge with the disease progression.

Neuroinflammation is considered one of the most important factors contributing critically to pathophysiology of PD . Recently, high mobility group box-1 (HMGB1) protein has been encoded as a potential inflammatory biomarker in PD. HMGB1 mediates immune response mostly through endothelial cells and macrophage activation via targeting two vital cell receptors; Toll-like receptor 4 (TLR4) and advanced glycation end products (RAGE). HMGB1 leads to a sequential cascade of inflammatory response through enhanced release of tumor necrosis factor-alpha (TNF-α) and interleukins (ILs), prominently IL-1β and IL-6. HMGB1 mediated also up-regulation of nuclear factor kappa-β (NF-κB) with subsequent flared pro-inflammatory storm.


Eligibility Criteria:
Inclusion Criteria:

* Age ≥ 18 years.
* Both male and female will be included.
* Patients diagnosed with PD according to Unified Parkinson's Disease Rating Scale.

Exclusion Criteria:

* Breast feeding
* Patients with significant liver and kidney function abnormalities.
* Alcohol and / or drug abusers.
* Patients with known allergy to the study medications
Comparative Psychiatric Problems Between First and Second Trimester Miscarriage

Description of the psychiatric impact of miscarriage on women.

miscarriage, a significant reproductive health issue, often has profound psychological implications for women. The emotional and psychiatric effects of abortion can vary widely based on individual, cultural, and situational factors, as well as the timing of the procedure (1). First-trimester abortions are typically more common and are generally less complex medically, while second-trimester abortions often involve more intricate decision-making processes and greater societal and personal stigma (2).

Emerging evidence suggests that women undergoing abortions in different trimesters may experience distinct psychiatric challenges, including anxiety, depression, and post-traumatic stress disorder. However, the comparative psychological burden between first- and second-trimester abortions remains underexplored (3-6). Understanding these differences is crucial for tailoring mental health interventions and providing comprehensive care to affected women.

This study aims to compare the prevalence and types of psychiatric problems in mothers undergoing abortion in the first versus the second trimester, thereby contributing to the body of knowledge on maternal mental health and informing evidence-based support strategies.

Eligibility Criteria:
Inclusion Criteria:

* all miscarrying women less than or equal to 26 weeks gestation

Exclusion Criteria:

* ectopic pregnancy and vesicular mole
A Study of The Safety Profile of First-line Avastin (Bevacizumab) in Combination With Paclitaxel in Patients With Locally Recurrent or Metastatic Her2-negative Breast Cancer (AVATAX)

This single arm, open label study will assess the safety profile of Avastin (bevacizumab) in combination with paclitaxel as first-line treatment in patients with locally recurrent or metastatic Her2-negative breast cancer. Patients will receive Avastin, either 10 mg/kg intravenously (iv) every 2 weeks or 15 mg/kg iv every 3 weeks. Correspondingly, paclitaxel will be administered at a dose of 90 mg/m2 o days 1, 8 and 15 of every 28-day cycle or 175 mg/m2 on day 1 of every 21-day cycle. Anticipated time on study treatment is until disease progression or unacceptable toxicity occurs.


Eligibility Criteria:
Inclusion Criteria:

* Adult patients, \>/= 18 years of age
* Locally recurrent or metastatic Her2-negative breast cancer
* Locally recurrent disease must not be amenable to radiation therapy or resection with curative intent
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2
* Prior Adjuvant chemotherapy allowed; if taxane-based a disease-free interval after completion of \>/=12 months is required
* Adequate haematological, renal and liver function

Exclusion Criteria:

* Previous chemotherapy for locally recurrent or metastatic disease
* Radiation therapy for metastatic disease (except for relief of metastatic bone pain with irradiation of \</= 30% of marrow-bearing bone)
* CNS metastases
* Pre-existing peripheral neuropathy
* Clinically significant cardiovascular disease
Effects a Rehabilitation Program in Patients With Left Ventricular Dysfunction After Coronary Artery Bypass Grafting

This study aims to analyze effects of three types of cardiac rehabilitation protocol on fuctional capacity, inflammatory markers, pulmonary function and clinical outcomes after coronary artery bypass grafting (CABG) in patients with left ventricular disfunction. Patients will be randomized and allocated in three groups according to type of exercise protocol: 1. walk; 2. cycle; 3. functional electrical stimulation.

Several studies have been demonstrated beneficial effects of exercise to minimize impact of CABG. However, there is no consensus on what kind of exercise is safe and effective for patients with left ventricular dysfunction.

Walking

Eligibility Criteria:
Inclusion Criteria:

* Coronary artery disease proven by coronary angiography;
* Elective CABG;
* No acute or chronic pulmonary disease;
* Patients after surgery, keep in spontaneous ventilation on first postoperative day;
* Absence of neurological, neuromuscular, musculoskeletal and osteoarticular incapacitating;
* Consent form signed for participation in the survey.

Exclusion Criteria:

* Inability to perform spirometry;
* Presence of acute lung disease or chronic;
* Surgical indication of urgency;
* Morbid obesity;
* Hemodynamics instability at the time of spirometry or during six minutes walking test;
* Intraoperative death or until the sixth postoperative day;
* Patients remaining in mechanical prolonged ventilation for more than 12 hours;
* Severe cardiac arrhythmia during application of assessment protocols and exercises (ventricular tachycardia, atrioventricular block second or degree) any other condition the investigator's discretion put the patient at increased risk with beginning of the year; Any change that may lead to failure of proposed protocols.
The Effect of Massage on the Bilirubin Level in Term Infants Receiving Phototherapy

Background: It has been reported in the current literature that massage has various positive physiological effects on the newborn. Also baby massage; It increases the collection and excretion of waste products such as bilirubin by accelerating the flow of blood, lymph and tissue fluids. Our aim is to investigate the effect of infant massage on hyperbilirubinemia in newborns receiving phototherapy.

Method: The population of the study consisted of babies who were hospitalized in Istanbul Haseki Training and Research Hospital Neonatal Intensive Care Unit between October 2021 and January 2022 and needed phototherapy. Transcutaneous bilirubin device and data collection form were used to obtain the data. 61 newborns who met the study criteria were randomly divided into experimental (n=30) and control (n=31) groups. Phototherapy was applied to all babies twice a day. In addition to phototherapy, infant massage was applied to the experimental group for 10 minutes just before the phototherapy. Bilirubin level measurements were made 2 hours after the end of phototherapy for both groups. Diaper changes for both groups were carried out 8 times a day, every 3 hours.


Eligibility Criteria:
Inclusion Criteria:

* Born between 37-42 gestational weeks
* Birth weight between 2500-4000gr
* 1st and 5th Apgar score between 7-10
* Needing phototherapy treatment
* Diagnosed with indirect hyperbilirubinemia 24 hours or more after birth
* Orally fed
* No health problems other than indirect hyperbilirubinemia
* Newborns who has stable vital signs

Exclusion Criteria:

* ABO blood incompatibility or Rh incompatibility
* Diagnosed with direct hyperbilirubinemia
* Newborns who has skin anomaly
* Needing fluid replacement
* Newborns with gastrointestinal disorders
The Effects on Pain of Acupressure and Foot Reflexology Before Heel Lancing in Newborns

This study aimed to determine the effects of foot reflexology and acupressure on the KI3 and St36 points on pain during interventions when these procedures were administered before heel lancing in term newborns.


Eligibility Criteria:
Inclusion Criteria:

1. Being born by cesarean section,
2. Being a term newborn,
3. Being completed the 24th hour of the postnatal period,
4. Staying with birth mother,
5. Being fed in the last half hour before the procedure,
6. Having a heel prick performed by the same nurse,
7. Giving blood on the first try (because pain level may change on the second try),
8. Having a mother who gave written informed consent

Exclusion Criteria:

1. Having no health problem,
2. Being underwent more than 2 invasive interventions,
3. Receiving an analgesic/sedative drug in the 8 hours before the application.